Ovarian Cancer Trial, RecruitingNCT04294927Sponsor: University Medical Center NijmegenCondition: Ovarian Cancer
Printed from Voxsanity (voxsanity.com.au) — NCT04294927 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
voxsanity.com.au ·
Eligibility summary from public government registries ·
18 August 2026 ·
not medical advice
Who may and may not be able to join
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who may be able to join
You are a woman who has been confirmed to carry a specific harmful gene mutation in one of these genes: BRCA1, BRCA2, RAD51C, RAD51D, or BRIP1, tested at one of the participating medical centres
Your age falls within the range linked to your specific gene mutation: BRCA1 carriers aged 25–40, BRCA2 carriers aged 25–45, or RAD51C/RAD51D/BRIP1 carriers aged 25–50
You have finished having children and do not plan to have any more
You still have at least one fallopian tube (the tubes that connect the ovaries to the uterus)
You may be able to join even if you have had a previous cancer diagnosis, as long as it was not ovarian, fallopian tube, or peritoneal cancer
You are willing and able to give written consent to take part in the trial
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
You have already gone through menopause, either naturally or as a result of medical treatment
You are planning to have your ovaries removed within two years of joining the trial
You are not legally able to make your own decisions about medical care
You have already had both fallopian tubes removed
You have a personal history of ovarian cancer, fallopian tube cancer, or peritoneal cancer
You are currently being diagnosed with or treated for any active cancer
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Principal Investigator: Joanne A. de Hullu, MD, PhD, Radboud University Medical Center
Royal Adelaide Hospital, Adelaide, South Australia
+61870740000
Frances Perry House, Melbourne, Victoria
+61393445000
Mercy Hospital, Melbourne, Victoria
+61 3 8458 4444
Epworth Hospital, Richmon, Victoria
+61394266666
Western Health, St Albans, Victoria
03 8345 1333
King Edward Memorial Hospital, Perth, Western Australia
+61864582222
The Mater Hospital, Brisbane,
+61394266666
Monash Health, Melbourne,
Peter MacCallum Centre, Melbourne,
Royal Womens Hospital, Melbourne,
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT04294927
Sponsor: University Medical Center Nijmegen
Phase: Not Applicable
Status: Recruiting
Condition: Ovarian Cancer
Trial contact: +31 (0) 24 36 16683
More information: https://clinicaltrials.gov/study/NCT04294927
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who may be able to join
You are a woman who has been confirmed to carry a specific harmful gene mutation in one of these genes: BRCA1, BRCA2, RAD51C, RAD51D, or BRIP1, tested at one of the participating medical centres
Your age falls within the range linked to your specific gene mutation: BRCA1 carriers aged 25–40, BRCA2 carriers aged 25–45, or RAD51C/RAD51D/BRIP1 carriers aged 25–50
You have finished having children and do not plan to have any more
You still have at least one fallopian tube (the tubes that connect the ovaries to the uterus)
You may be able to join even if you have had a previous cancer diagnosis, as long as it was not ovarian, fallopian tube, or peritoneal cancer
You are willing and able to give written consent to take part in the trial
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
You have already gone through menopause, either naturally or as a result of medical treatment
You are planning to have your ovaries removed within two years of joining the trial
You are not legally able to make your own decisions about medical care
You have already had both fallopian tubes removed
You have a personal history of ovarian cancer, fallopian tube cancer, or peritoneal cancer
You are currently being diagnosed with or treated for any active cancer
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 8 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Not Applicable
Sponsor
University Medical Center Nijmegen
Registry
ClinicalTrials.gov
Start date
1 March 2020
Est. completion
17 February 2040
Where this trial is recruiting
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇦 Canada
🇩🇪 Germany
🇮🇪 Ireland
🇮🇹 Italy
🇲🇽 Mexico
🇳🇱 Netherlands
🇳🇴 Norway
🇵🇱 Poland
🇪🇸 Spain
🇸🇪 Sweden
🇺🇸 United States
Uruguay
15 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
High grade serous (ovarian) cancer incidence
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.
Analytics cookies are set only if you accept. Advertising runs with personalisation
permanently off and is not changed by this choice — see our
Privacy Policy.